Discovering significant breakthroughs in fibrosis.
Blade Clinical Trials
Today, we are advancing a robust pipeline of potential first-in-class investigational small-molecule therapies to combat diseases of lung, liver and heart fibrosis, as well as neuro-degenerative conditions. This includes multiple direct inhibitors of autotaxin / LPA and dimeric calpains that offer distinct but complementary anti-fibrotic mechanisms.
Find Clinical Trials Near Me
|Program||Indication||Study Phase||Status||Trial number|
|BLD-0409||Healthy Volunteer Safety Testing||Phase 1||Complete||NCT04146805|
|BLD-0409-102||Relative Bioavailability||Phase 1b||In Process||NCT04814472|
|BLD-0409-103||Drug-Drug Interaction||Phase 1b||In Process||NCT04814498|
|BLD-0409-203||Idiopathic Pulmonary Fibrosis||Phase 2||Planned|
|BLD-0409-210||Interstitial Lung Disease||Phase 2||Planned|
Blade’s autotaxin inhibitor, BLD-0409, is being studied in a Phase 1 double-blind, randomized, placebo-controlled, multiple cohort, single and multiple ascending dose trial to assess safety, tolerability and pharmacokinetics in healthy participants (Clinicaltrials.gov NCT04146805).